Childhood Allergy Disease, Early Diagnosis, and the Potential of Salivary Protein Biomarkers

Table 5

Summary of MS-based methods used for salivary biomarker identification. The table is adapted from [56].

Disease	Saliva	Stimulation	Proteomics approach	Biomarkers	Verification methods	References	Sample size
Breast cancer	Whole	Stimulated	SELDI-TOF/MS	(i) c-erbB-2	(i) ELISA; (ii) Western blot	Streckfus et al., 2006	Control—3; Disease—3
Caries	Whole	Unstimulated	2-DE/MS	(i) Statherin 5; (ii) Cystatin	(i) Western blot	Rudney, et al., 2009	Control—18; Disease—23
Gastric cancer	Whole	Unstimulated	MALDI-TOF/MS	(i) 1472.78 Da; (ii) 2936.49 Da; (iii) 6556.81 Da; (iv) 7081.17 Da	—	Wu, 2009	Control—18; Disease—23
Graft versus host disease	SM/SL	Stimulated	SELDI-TOF/MS MALDI-TOF/MS	(i) Lactoferrin; (ii) SLPI; (iii) IgA; (iv) b2-microglobulin	(i) ELISA	Imanguli et al., 2007	Control—0; Disease—41
HNSC	Whole	Stimulated	LC–MS/MS	(i) Complement factor B	(i) Western blot	Ohshiro et al., 2007	Control—5; Disease—3
Oral lichen planus	Whole	Unstimulated	2-DE MALDI-TOF/MS	(i) Urinary prokallikrein; (ii) PLUNC	—	Yang et al.,2006	Control—6; Disease—6
OSCC	Whole	Unstimulated	2-DE/MS; LC–MS/MS	(i) M2BP; (ii) Catalase; (iii) Profiling1; (iv) CD59; (v) MRP14	(i) ELISA; (ii) Western blot	Hu et al., 2008	Control—64; Disease—64
Pulmonary disease	Whole	Unstimulated	2-DE/MS	(i) Lipocalin; (ii) Apolipoprotein A1	—	Nicholas et al., 2010	Control—20; Disease—25
Type 1 diabetes	Whole	Stimulated	2-DE MALDI-TOF/MS	(i) α-amylase; (ii) Cystatin; (iii) PIP	—	Hirtz et al., 2006	Control—8; Disease—8
Type 2 diabetes	Whole	Unstimulated	LC–MS/MS	(i) A1AT; (ii) α-2-macroglobulin; (iii) Cystatin C; (iv) Transthyretin	(i) ELISA	Rao et al., 2009	Control—10; Disease—30

SM represents submandibular; SL represents sublingual; HNSC represents head and neck squamous carcinoma; OSCC represents oral squamous cell carcinoma; SS represents Sjögren’s syndrome.